These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34608266)

  • 21. Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer.
    Lai YW; Hsu WJ; Lee WY; Chen CH; Tsai YH; Dai JZ; Yang CC; Lin CW
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
    Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
    Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer.
    Ji H; Sang M; Liu F; Ai N; Geng C
    Pathol Res Pract; 2019 Apr; 215(4):697-704. PubMed ID: 30611621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of MGP by HOXC8 promotes the proliferation, migration, and EMT processes of triple-negative breast cancer.
    Gong C; Zou J; Zhang M; Zhang J; Xu S; Zhu S; Yang M; Li D; Wang Y; Shi J; Li Y
    Mol Carcinog; 2019 Oct; 58(10):1863-1875. PubMed ID: 31264274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
    Zhang KJ; Hu Y; Luo N; Li X; Chen FY; Yuan JQ; Guo L
    Int J Oncol; 2020 May; 56(5):1240-1251. PubMed ID: 32319565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.
    Lv ZD; Yang DX; Liu XP; Jin LY; Wang XG; Yang ZC; Liu D; Zhao JJ; Kong B; Li FN; Wang HB
    Cell Physiol Biochem; 2017; 44(5):1785-1795. PubMed ID: 29216628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor.
    Kim HY; Ha Thi HT; Hong S
    Cancer Lett; 2018 Feb; 415():30-39. PubMed ID: 29217458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sphingosine 1-phosphate signaling induces SNAI2 expression to promote cell invasion in breast cancer cells.
    Wang W; Hind T; Lam BWS; Herr DR
    FASEB J; 2019 Jun; 33(6):7180-7191. PubMed ID: 30844311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
    Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
    Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD155 contributes to the mesenchymal phenotype of triple-negative breast cancer.
    Zheng Q; Gao J; Yin P; Wang W; Wang B; Li Y; Zhao C
    Cancer Sci; 2020 Feb; 111(2):383-394. PubMed ID: 31830330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
    Kim S; Lee J; Jeon M; Nam SJ; Lee JE
    Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SOX9 Is Essential for Triple-Negative Breast Cancer Cell Survival and Metastasis.
    Ma Y; Shepherd J; Zhao D; Bollu LR; Tahaney WM; Hill J; Zhang Y; Mazumdar A; Brown PH
    Mol Cancer Res; 2020 Dec; 18(12):1825-1838. PubMed ID: 32661114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. STAT3 Targets
    Ma JH; Qi J; Lin SQ; Zhang CY; Liu FY; Xie WD; Li X
    Mol Cancer Res; 2019 Nov; 17(11):2184-2195. PubMed ID: 31427441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer.
    Zhang FL; Cao JL; Xie HY; Sun R; Yang LF; Shao ZM; Li DQ
    Cancer Res; 2018 Oct; 78(20):5780-5792. PubMed ID: 30093560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epithelial-mesenchymal transition induced PAI-1 is associated with prognosis of triple-negative breast cancer patients.
    Xu J; Zhang W; Tang L; Chen W; Guan X
    Gene; 2018 Sep; 670():7-14. PubMed ID: 29802992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer.
    Al-Khadairi G; Naik A; Thomas R; Al-Sulaiti B; Rizly S; Decock J
    J Transl Med; 2019 Jan; 17(1):9. PubMed ID: 30602372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERα Signaling Pathway in High-level MZF1-expressing TNBC cells.
    Yue CH; Liu JY; Chi CS; Hu CW; Tan KT; Huang FM; Pan YR; Lin KI; Lee CJ
    Anticancer Res; 2019 Aug; 39(8):4149-4164. PubMed ID: 31366500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiation exposure triggers the progression of triple negative breast cancer via stabilizing ZEB1.
    Lin Y; Bai X; Zhou W; He Y; Wu Y; Wang X
    Biomed Pharmacother; 2018 Nov; 107():1624-1630. PubMed ID: 30257380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.
    Li K; Ying M; Feng D; Chen Y; Wang J; Wang Y
    Oncol Rep; 2016 Apr; 35(4):2405-12. PubMed ID: 26781859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pro-metastasis effect of circANKS1B in breast cancer.
    Zeng K; He B; Yang BB; Xu T; Chen X; Xu M; Liu X; Sun H; Pan Y; Wang S
    Mol Cancer; 2018 Nov; 17(1):160. PubMed ID: 30454010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.